Results 81 to 90 of about 840,777 (236)

Just how difficult can it be counting up R&D funding for emerging technologies (and is tech mining with proxy measures going to be any better?) [PDF]

, 2013
Decision makers considering policy or strategy related to the development of emerging technologies expect high quality data on the support for different technological options. A natural starting point would be R&D funding statistics.
Anon, Archibuigi D., Augsdorfer P., Bijker W. E., Bowker G., Freeman C., Headrick D., Jaffe A. B., Josh Siepel, Martin P., Matthews K., Michael M. Hopkins, Morgan Jones M., NESTA, Nicholaisen J., Nuffield Council on Bioethics, OECD, OECD. 2009, Porter T., Rafols I., Rosenberg N., Searle J., Veugelers R.   +22 more
core   +1 more source

Research progress on the metabolic transformation of Shenling Baizhu San under the influence of the gut microbiota

Advanced Chinese Medicine, EarlyView.
Abstract The gut microbiota plays a pivotal role in maintaining host metabolic homeostasis and overall physiological functions. Shenling Baizhu San (SLBZS), a time‐honored classical prescription for tonifying Qi, strengthening the spleen, removing dampness, and arresting diarrhea, has shown broad clinical efficacy in digestive disorders.
Jinlan Di, Xiaochun Zhang
wiley   +1 more source

Prospects for the Use of Medical Clays (Review)

Разработка и регистрация лекарственных средств, 2019
Introduction. The article deals with the aspects of the use of Medical Clays in Pharmaceutical Technology. A review of the traditional areas of application of Medical Clay, as well as highlighting new directions.Text. One of the main problems of domestic
A. V. Bondarev, E. T. Zhilyakova, N. B. Demina, E. Yu. Timoshenko   +3 more
doaj   +1 more source

Expert consensus on research paradigms and technological layout for clinical priority diseases in traditional Chinese medicine: Rheumatoid arthritis

Advanced Chinese Medicine, EarlyView.
Abstract Rheumatoid arthritis (RA) is a chronic, highly disabling autoimmune disease. Although modern medical treatments have made progress, challenges such as suboptimal efficacy, relapse, difficulties in comorbidity management, and side effects persist.
Dier Jin, Jinping Wang, Zihan Wang, Mei Mo, Xiaojing Liu, Nan Zhang, Xiaoxiao Zhang, Qingwen Tao, Yuan Xu   +8 more
wiley   +1 more source

The design of licensing contracts: Chemicals, Pharmaceuticals, and Electrical Engineering in Imperial Germany [PDF]

We investigate a sample of 180 technology licensing contracts closed by German chemical, pharmaceutical, and electrical engineering companies between 1880 and 1913.
Carsten Burhop, Thorsten Lübbers
core  

Influence of pH and gelatin concentration on the size and zeta potential of gelatin colloidal dispersions [PDF]

, 2016
Gelatin is a heterogeneous mixture of water-soluble proteins. Its broad molecular weight profile may be responsible for the variation in the experimental conditions required for nanoparticle formation.
10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Farrugia, Claude, Mallia, Lothar, Sinagra, Emmanuel   +3 more
core  

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, Johanna Oechtering, Sabine Schaedelin, Lisa Hofer, Amar Zadic, Juan Francisco Vilchez Gomez, Lester Melie‐Garcia, Alessandro Cagol, Riccardo Galbusera, Sebastian Finkener, Patrice Lalive, Marjolaine Uginet, Stefanie Müller, Caroline Pot, Amandine Mathias, Renaud Du Pasquier, Robert Hoepner, Andrew Chan, Giulio Disanto, Chiara Zecca, Marcus D’Souza, Lars G. Hemkens, Tobias Derfuss, Özgür Yaldizli, Patrick Roth, Claudio Gobbi, David Brassat, Björn Tackenberg, Henrik Zetterberg, Tjalf Ziemssen, Heinz Wiendl, Klaus Berger, Marco Hermesdorf, Fredrik Piehl, Ludwig Kappos, Cristina Granziera, Ahmed Abdelhak, David Leppert, Eline A. J. Willemse, Pascal Benkert, Jens Kuhle, Swiss Multiple Sclerosis Cohort Study (SMSC)   +43 more
wiley   +1 more source

The rs10191329 Risk Allele Is Associated With Pronounced Retinal Layer Atrophy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate whether the rs10191329 risk allele in the DYSF–ZNF638 locus, which is implicated in central nervous system resilience rather than immune‐mediated pathology, is associated with retinal layer thinning, a biomarker of neuroaxonal damage in relapsing multiple sclerosis (RMS). Methods From a prospective observational study,
Gabriel Bsteh, Ruchi Tanavade, Nik Krajnc, Fabian Föttinger, Theresa König, Martin Krenn, Lukas Haider, Barbara Kornek, Fritz Leutmezer, Kerstin U. Ludwig, Stefan Macher, Tobias Monschein, Markus Ponleitner, Paulus Rommer, Christiane Schmied, Karin Zebenholzer, Tobias Zrzavy, Gudrun Zulehner, Franziska Di Pauli, Axel Schmidt, Harald Hegen, Berthold Pemp, Thomas Berger   +22 more
wiley   +1 more source

Product cycles, innovation and exports: A study of Indian pharmaceuticals [PDF]

This paper sheds light on the product cycle and neotechnology theories of trade in the context of generic pharmaceuticals. The paper studies the export performance of 177 Indian pharmaceutical firms for the post- liberalization period 1991-2004.
Alka Chadha
core  

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source